KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Change in Receivables (2016 - 2020)

Historic Change in Receivables for Thermo Fisher Scientific (TMO) over the last 12 years, with Q4 2020 value amounting to $444.0 million.

  • Thermo Fisher Scientific's Change in Receivables rose 56250.0% to $444.0 million in Q4 2020 from the same period last year, while for Dec 2020 it was $1.3 billion, marking a year-over-year increase of 47866.67%. This contributed to the annual value of $171.0 million for FY2024, which is 29767.44% up from last year.
  • Per Thermo Fisher Scientific's latest filing, its Change in Receivables stood at $444.0 million for Q4 2020, which was up 56250.0% from $663.0 million recorded in Q3 2020.
  • In the past 5 years, Thermo Fisher Scientific's Change in Receivables registered a high of $663.0 million during Q3 2020, and its lowest value of -$96.0 million during Q4 2019.
  • Moreover, its 5-year median value for Change in Receivables was $49.6 million (2016), whereas its average is $130.4 million.
  • Per our database at Business Quant, Thermo Fisher Scientific's Change in Receivables surged by 762903.23% in 2016 and then tumbled by 23076.92% in 2019.
  • Thermo Fisher Scientific's Change in Receivables (Quarter) stood at $239.6 million in 2016, then decreased by 16.11% to $201.0 million in 2017, then surged by 50.25% to $302.0 million in 2018, then crashed by 131.79% to -$96.0 million in 2019, then soared by 562.5% to $444.0 million in 2020.
  • Its Change in Receivables stands at $444.0 million for Q4 2020, versus $663.0 million for Q3 2020 and -$23.0 million for Q2 2020.